Bevacizumab for treatment of choroidal neovascularization secondary to candida chorioretinitis
To report a case of juxtafoveal choroidal neovascularization in a patient with candida chorioretinitis successfully treated with intravitreal bevacizumab.
A 45-year-old woman previously treated for candida chorioretinitis was presented with reduced vision in the left eye. The patient was investigated with ophthalmoscopy, fluorescein angiography, and optical coherence tomography (OCT). Following initial treatment, fundus examination, fluorescein angiography, and OCT of the right eye revealed a secondary juxtafoveal classic choroidal neovascularization. Following a single intravitreal injection of bevacizumab, the patient had excellent visual recovery, with absence of subretinal or intraretinal fluid in the OCT.
Bevacizumab was effective in treatment of choroidal neovascularization associated with candida chorioretinitis.
KeywordsCandida Chorioretinitis Choroidal neovascular membrane Bevacizumab
RWJL and ADD received funding from the National Institute for Health Research (NIHR) Biomedical Research Centre based at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health.
Compliance with ethical standards
Conflicts of interest
None of the authors have any proprietary interest in the materials described in this study.
This report is limited to secondary use of information previously collected in the course of normal care (without an intention to use it for research at the time of collection) and therefore excluded from REC review.